112 related articles for article (PubMed ID: 11595346)
21. Trafficking-dependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells.
Apparsundaram S; Sung U; Price RD; Blakely RD
J Pharmacol Exp Ther; 2001 Nov; 299(2):666-77. PubMed ID: 11602680
[TBL] [Abstract][Full Text] [Related]
22. The role of cysteines and histidins of the norepinephrine transporter.
Wenge B; Bönisch H
Neurochem Res; 2013 Jul; 38(7):1303-14. PubMed ID: 23525969
[TBL] [Abstract][Full Text] [Related]
23. The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.
Zhu MY; Kyle PB; Hume AS; Ordway GA
Neurochem Res; 2004 Feb; 29(2):419-27. PubMed ID: 15002740
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter.
Runkel F; Brüss M; Nöthen MM; Stöber G; Propping P; Bönisch H
Pharmacogenetics; 2000 Jul; 10(5):397-405. PubMed ID: 10898109
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.
Paczkowski FA; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2001 Dec; 97(1):32-42. PubMed ID: 11744160
[TBL] [Abstract][Full Text] [Related]
26. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.
Mason JN; Deecher DC; Richmond RL; Stack G; Mahaney PE; Trybulski E; Winneker RC; Blakely RD
J Pharmacol Exp Ther; 2007 Nov; 323(2):720-9. PubMed ID: 17673606
[TBL] [Abstract][Full Text] [Related]
27. Norepinephrine transporter splice variants and their interaction with substrates and blockers.
Kitayama S; Dohi T
Eur J Pharmacol; 2003 Oct; 479(1-3):65-70. PubMed ID: 14612138
[TBL] [Abstract][Full Text] [Related]
28. A second extracellular site is required for norepinephrine transport by the human norepinephrine transporter.
Wang CI; Shaikh NH; Ramu S; Lewis RJ
Mol Pharmacol; 2012 Nov; 82(5):898-909. PubMed ID: 22874414
[TBL] [Abstract][Full Text] [Related]
29. Effects of serine mutations in transmembrane domain 7 of the human norepinephrine transporter on substrate binding and transport.
Danek Burgess KS; Justice JB
J Neurochem; 1999 Aug; 73(2):656-64. PubMed ID: 10428062
[TBL] [Abstract][Full Text] [Related]
30. Functional consequences of homo- but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters.
Kocabas AM; Rudnick G; Kilic F
J Neurochem; 2003 Jun; 85(6):1513-20. PubMed ID: 12787070
[TBL] [Abstract][Full Text] [Related]
31. Norepinephrine transporters in rat placenta labeled with [3H]nisoxetine.
Shearman LP; Meyer JS
J Pharmacol Exp Ther; 1998 Feb; 284(2):736-43. PubMed ID: 9454822
[TBL] [Abstract][Full Text] [Related]
32. Antipeptide antibodies confirm the topology of the human norepinephrine transporter.
Brüss M; Hammermann R; Brimijoin S; Bönisch H
J Biol Chem; 1995 Apr; 270(16):9197-201. PubMed ID: 7721836
[TBL] [Abstract][Full Text] [Related]
33. Characterization of cocaine and antidepressant-sensitive norepinephrine transporters in rat placental trophoblasts.
Jayanthi LD; Vargas G; DeFelice LJ
Br J Pharmacol; 2002 Apr; 135(8):1927-34. PubMed ID: 11959795
[TBL] [Abstract][Full Text] [Related]
34. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
Melikian HE; Ramamoorthy S; Tate CG; Blakely RD
Mol Pharmacol; 1996 Aug; 50(2):266-76. PubMed ID: 8700133
[TBL] [Abstract][Full Text] [Related]
35. Investigation of the functional roles of the MELAL and GQXXRXG motifs of the human noradrenaline transporter using cysteine mutants.
Sucic S; Bryan-Lluka LJ
Eur J Pharmacol; 2007 Feb; 556(1-3):27-35. PubMed ID: 17141753
[TBL] [Abstract][Full Text] [Related]
36. Voltammetric studies on mechanisms of dopamine efflux in the presence of substrates and cocaine from cells expressing human norepinephrine transporter.
Chen N; Trowbridge CG; Justice JB
J Neurochem; 1998 Aug; 71(2):653-65. PubMed ID: 9681456
[TBL] [Abstract][Full Text] [Related]
37. The N-terminus of the norepinephrine transporter regulates the magnitude and selectivity of the transporter-associated leak current.
Binda F; Lute BJ; Dipace C; Blakely RD; Galli A
Neuropharmacology; 2006 Mar; 50(3):354-61. PubMed ID: 16289633
[TBL] [Abstract][Full Text] [Related]
38. A previously undescribed intron and extensive 5' upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene.
Kim CH; Kim HS; Cubells JF; Kim KS
J Biol Chem; 1999 Mar; 274(10):6507-18. PubMed ID: 10037744
[TBL] [Abstract][Full Text] [Related]
39. Cell surface trafficking of the antidepressant-sensitive norepinephrine transporter revealed with an ectodomain antibody.
Savchenko V; Sung U; Blakely RD
Mol Cell Neurosci; 2003 Dec; 24(4):1131-50. PubMed ID: 14697674
[TBL] [Abstract][Full Text] [Related]
40. Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells.
Zavosh A; Schaefer J; Ferrel A; Figlewicz DP
Brain Res Bull; 1999 Jul; 49(4):291-5. PubMed ID: 10424850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
